Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant

Oral NEPA is the fixed‐combination antiemetic comprising netupitant (neurokinin‐1 receptor antagonist [NK(1)RA]) and palonosetron (5‐hydroxytryptamine‐3 receptor antagonist [5‐HT(3) RA]). Intravenous (IV) NEPA, containing fosnetupitant, a water‐soluble N‐phosphoryloxymethyl prodrug of netupitant, ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyler, Timothy, Schultz, Armin, Venturini, Alessio, Giuliano, Claudio, Bernareggi, Alberto, Spezia, Riccardo, Voisin, Daniel, Stella, Valentino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092591/
https://www.ncbi.nlm.nih.gov/pubmed/36263927
http://dx.doi.org/10.1002/cpdd.1183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092591/
https://www.ncbi.nlm.nih.gov/pubmed/36263927
http://dx.doi.org/10.1002/cpdd.1183

Ejemplares similares